MedTrace Logo

Usefulness of 18F-FDG PET/CT in the Initial Staging and Surveillance of Endometrial Cancer Patients

NCT05056259 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2021-10-25

No results posted yet for this study

Summary

1. To assess the value of 18F-FDG PET/CT in the initial staging and detection of recurrent cases of endometrial cancer.
2. To determine correlation between PET/CT derived parameters including SUVmax, TLG and MTV and clinic-pathological patient characteristics.
3. To detect local and distant recurrence after therapy.

Conditions

Interventions

DEVICE

18F-FDG PET/CT

The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be \<150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection. MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region. Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes. PET/CT data will include tumor size and extension, LN invasion\& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG \& MTV will be calculated for primary tumor. Data of PET will be compared with other diagnostic imaging and postoperative pathologic data.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hanan Gamaleldin Mostafa, M.D · Professor

  • Esraa Roshdey Hassan, M.D · Doctor

Eligibility

Min Age
30 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-09-30
Completion
2023-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05056259 on ClinicalTrials.gov